I am a doctor and not a lawyer...I hope for all the longs that you are correct in your assessment..
I am nervous about the fact that even though the generics have whittled themselves down to straw: they have managed to get their toe inside the Amarin door...Drug labeling and physician behavior are not always predictable...How do you police doctors in their offices..The FDA is not designed to scrutinize the behavior of clinicians...The only exception to that rule I have seen in forty years was the injection of liquid silicone.
There is going to be little or no objection to generic Vascepa in the medical community..Drugs like Repatha and other injectables have the effect of making doctors advocates for cheaper prices...And so are the drug plans..It is very unlikely IMO that they are going to police doctors who violate arbitrary issues like how long a patient will need to be on a drug...So even though most Vascepa patients might need to be on the drug until they expire..There are currently no requirements that doctors need to certify the expected length the patient will be on the drug..And if the doctor is questioned he can merely explain in his opinion the patient needed to be on the drug longer than expected.. The insurance companies also are going to favor the cheaper priced drug..So it is going to be very difficult to monitor the conversion of V into generic V....
Hamoa, this post was so good I gave it a whole PlusOneCoin. A whole one!
That is like buying a box of cereal, and noticing that the entire box is COVERED with those little squares kids take to school to get a dress down day, and the school gets free cheese or computers or something.
"The offers to settle, from Amarin,, will only get smaller by the day."
I don't like the idea of AMRN making any settlement offer. If AMRN can expand the label into other areas then wouldn't they be able to extend the patent life?